MA55781A - COMBINATION THERAPIES INCLUDING APRMILAST AND TYK2 INHIBITORS - Google Patents

COMBINATION THERAPIES INCLUDING APRMILAST AND TYK2 INHIBITORS

Info

Publication number
MA55781A
MA55781A MA055781A MA55781A MA55781A MA 55781 A MA55781 A MA 55781A MA 055781 A MA055781 A MA 055781A MA 55781 A MA55781 A MA 55781A MA 55781 A MA55781 A MA 55781A
Authority
MA
Morocco
Prior art keywords
aprmilast
combination therapies
therapies including
tyk2 inhibitors
tyk2
Prior art date
Application number
MA055781A
Other languages
French (fr)
Inventor
Mary Adams
Lisa Beebe
Gilles Buchwalter
Tiffany Carr
Robert Plenge
Peter Henry Schafer
Te-Chen Tzeng
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Priority to MA055781A priority Critical patent/MA55781A/en
Publication of MA55781A publication Critical patent/MA55781A/en

Links

MA055781A 2019-04-30 2019-04-30 COMBINATION THERAPIES INCLUDING APRMILAST AND TYK2 INHIBITORS MA55781A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MA055781A MA55781A (en) 2019-04-30 2019-04-30 COMBINATION THERAPIES INCLUDING APRMILAST AND TYK2 INHIBITORS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MA055781A MA55781A (en) 2019-04-30 2019-04-30 COMBINATION THERAPIES INCLUDING APRMILAST AND TYK2 INHIBITORS

Publications (1)

Publication Number Publication Date
MA55781A true MA55781A (en) 2022-03-09

Family

ID=82258120

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055781A MA55781A (en) 2019-04-30 2019-04-30 COMBINATION THERAPIES INCLUDING APRMILAST AND TYK2 INHIBITORS

Country Status (1)

Country Link
MA (1) MA55781A (en)

Similar Documents

Publication Publication Date Title
MA55799A (en) COMBINATION THERAPIES INCLUDING APRMILAST AND TYK2 INHIBITORS
IL282487A (en) TYK2 inhibitors and their use
IL286248A (en) tyk2 inhibitors and their use
GB201909190D0 (en) Therapeutic agents
MA44890A (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
GB201909191D0 (en) Therapeutic agents
GB201909194D0 (en) Therapeutic agents
EP3906029A4 (en) MENIN-MLL INTERACTION INHIBITORS
PH12021551282A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
MA46716A (en) CELL THERAPY AND MICROGLIA INHIBITOR POLYTHERAPY
IL284799A (en) TYK2 inhibitors and uses thereof
MA52165A (en) SELECTIVE TGFBETA1 ISOFORM INHIBITORS AND ASSOCIATED USE
EP3773605A4 (en) MODIFIED HINGE-REGION 1 AND / OR 4 DYSTROPHINS FOR DYSTROPHINOPATHY THERAPY
IL279810A (en) Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
EP3609864A4 (en) HDAC6 INHIBITORS AND IMAGING AGENTS
EP4103186A4 (en) MONOTHERAPIES AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS
GB201902277D0 (en) Therapeutic agents
MA47074A (en) DOSAGE FORMS CONSISTING OF TASK-1 AND TASK-3 CHANNEL INHIBITORS AND THEIR USE IN THE TREATMENT OF RESPIRATORY DISORDERS
IL287704A (en) Use of cannabidiol in the treatment of multiple sclerosis complex
GB201905520D0 (en) Compounds and their therapeutic use
EP3820382C0 (en) SYSTEMS INCLUDING ALIGNMENT GUIDES AND IMPLANTS
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
GB201918541D0 (en) Therapeutic compounds and their use
IL279178A (en) Modified cas9 protein and use thereof
GB201906804D0 (en) Therapeutic agents